Cambrian BioPharma Inc

Cambrian BioPharma Inc is a declared insider of Faeth Therapeutics, Inc., with filings sourced from SEC (Form 4). We count 80 filings; the first trade dates from 8 February 2021 and the latest from 1 June 2026.

In open-market terms, that means 64 purchases worth €3.6M on one side and 10 sales worth €678k on the other. Netting one side against the other leaves €2.9M of net buying. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 3 share grants and 1 option exercise. 2026 to date brings no purchases and 2 sales.

In size, the median ticket on the buying side is €39k. Measured against the company's value, the median purchase equals 0.077% of market capitalisation, across 3 purchases where it is known. 61 out of 61 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 52 purchases show a median change of -44.1%, with the price up in 0% of them. This is a record of the past, not a forecast.

The latest filing, published on 1 June 2026, reports an open-market sale of €8,664 in Faeth Therapeutics, Inc. The clock since the last published purchase (10 June 2022) now reads 1,597 days. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.